{"name":"Janssen Pharmaceutical K.K.","slug":"janssen-pharmaceutical-k-k","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"cardiovascular","drugs":[{"name":"Erdafitinib Intravesical Delivery System","genericName":"Erdafitinib Intravesical Delivery System","slug":"erdafitinib-intravesical-delivery-system","indication":"Other","status":"phase_1"},{"name":"ITCZ-IV","genericName":"ITCZ-IV","slug":"itcz-iv","indication":"Invasive aspergillosis","status":"phase_3"},{"name":"JNJ-54861911, 50 mg","genericName":"JNJ-54861911, 50 mg","slug":"jnj-54861911-50-mg","indication":"Other","status":"phase_2"},{"name":"JNJ-56021927 240 Milligram","genericName":"JNJ-56021927 240 Milligram","slug":"jnj-56021927-240-milligram","indication":"Other","status":"phase_1"},{"name":"JNS001","genericName":"JNS001","slug":"jns001","indication":"Other","status":"phase_3"},{"name":"Placebo A (After CP)","genericName":"Placebo A (After CP)","slug":"placebo-a-after-cp","indication":"Other","status":"phase_3"},{"name":"Placebo B (After CP)","genericName":"Placebo B (After CP)","slug":"placebo-b-after-cp","indication":"Other","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"CNTO 148","genericName":"CNTO 148","slug":"cnto-148","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"CNTO 1959","genericName":"CNTO 1959","slug":"cnto-1959","indication":"Psoriasis","status":"phase_2"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"JNS020QD","genericName":"JNS020QD","slug":"jns020qd","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"ITCZ Oral Solution","genericName":"ITCZ Oral Solution","slug":"itcz-oral-solution","indication":"Oropharyngeal candidiasis","status":"phase_3"}]}],"pipeline":[{"name":"JNS020QD","genericName":"JNS020QD","slug":"jns020qd","phase":"phase_3","mechanism":"JNS020QD is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"CNTO 148","genericName":"CNTO 148","slug":"cnto-148","phase":"phase_3","mechanism":"CNTO 148 is a monoclonal antibody that blocks tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling in immune-mediated diseases.","indications":["Rheumatoid arthritis","Crohn's disease","Ulcerative colitis"],"catalyst":""},{"name":"CNTO 1959","genericName":"CNTO 1959","slug":"cnto-1959","phase":"phase_2","mechanism":"CNTO 1959 is a monoclonal antibody that inhibits IL-23 signaling to reduce inflammatory immune responses.","indications":["Psoriasis","Inflammatory bowel disease"],"catalyst":""},{"name":"Erdafitinib Intravesical Delivery System","genericName":"Erdafitinib Intravesical Delivery System","slug":"erdafitinib-intravesical-delivery-system","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ITCZ Oral Solution","genericName":"ITCZ Oral Solution","slug":"itcz-oral-solution","phase":"phase_3","mechanism":"ITCZ (itraconazole) is an azole antifungal that inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane.","indications":["Oropharyngeal candidiasis","Esophageal candidiasis","Systemic fungal infections (aspergillosis, blastomycosis, histoplasmosis, cryptococcosis)"],"catalyst":""},{"name":"ITCZ-IV","genericName":"ITCZ-IV","slug":"itcz-iv","phase":"phase_3","mechanism":"ITCZ-IV is an intravenous formulation of itraconazole, a triazole antifungal that inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane.","indications":["Invasive aspergillosis","Blastomycosis","Histoplasmosis","Cryptococcosis"],"catalyst":""},{"name":"JNJ-54861911, 50 mg","genericName":"JNJ-54861911, 50 mg","slug":"jnj-54861911-50-mg","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNJ-56021927 240 Milligram","genericName":"JNJ-56021927 240 Milligram","slug":"jnj-56021927-240-milligram","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNS001","genericName":"JNS001","slug":"jns001","phase":"phase_3","mechanism":"JNS001 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or inflammatory pathway to modulate immune response.","indications":[],"catalyst":""},{"name":"Placebo A (After CP)","genericName":"Placebo A (After CP)","slug":"placebo-a-after-cp","phase":"phase_3","mechanism":"Placebo A is an inert control substance with no active pharmacological mechanism.","indications":[],"catalyst":""},{"name":"Placebo B (After CP)","genericName":"Placebo B (After CP)","slug":"placebo-b-after-cp","phase":"phase_3","mechanism":"Placebo B is an inert control substance with no active pharmacological mechanism.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE9uSDlYWEpJYXdhQ2drQzhYOHJLd0twQ2Y1WE9rdGlISEk2ZngwWG9ETDNGMHpKQ2Utb0tVcGFNTGVvdEt6VjN1aWE0YWlMaThtd3l2TVdYQ3Z0cEw1RDJFZHlkZnU2WEZUMTdJdGd3ZHFzNUk?oc=5","date":"2025-10-15","type":"trial","source":"tandfonline.com","summary":"HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors: Future Oncology: Vol 21, No 25 - tandfonline.com","headline":"HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors: F","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE43YWZmalNrYmNvemxkU2tUWnVfLUpLdDZ4dG1MMTB3djVVSERoWTJiR3FiYzVDZ0gzdVdTVW9aS0w1eERyWGc5YUZVSm5EdEhMTEN1T0plYVpBc3JlVzVqeWZWa0VHLWMw?oc=5","date":"2025-09-09","type":"trial","source":"Wiley Online Library","summary":"Efficacy of ciclosporin monotherapy in non-severe aplastic anaemia not requiring transfusions: Results from a multicentre phase II study - Wiley Online Library","headline":"Efficacy of ciclosporin monotherapy in non-severe aplastic anaemia not requiring transfusions: Results from a multicentr","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE16Sm5pRWRrQTdFWjQ3bDVMbVlCRkdsOXJITHk4bl9MMXFmQ0VqalgwY05ZVkR5c0NzSW1kUEx1WGVkZ1NtLVNUYk94WHdCc09XWW15aEp0dTBhN21KcEhB?oc=5","date":"2025-04-25","type":"pipeline","source":"Nature","summary":"Impact of single dose of pegfilgrastim on peripheral blood stem cell harvest in patients with multiple myeloma or malignant lymphoma - Nature","headline":"Impact of single dose of pegfilgrastim on peripheral blood stem cell harvest in patients with multiple myeloma or malign","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE52RHY2NXZES0ZXRVF1MF95VWVGRWRnTDZsR0kza04zdHpVaDg1WnU4VjBDLUhfa2ZCTmYwVXVYcWphb3dwZU51MGVQbnp6T01WNVcwMHRTa1IwRXNz?oc=5","date":"2024-08-29","type":"trial","source":"EurekAlert!","summary":"New study assesses the efficacy of suvorexant in reducing delirium in older adults - EurekAlert!","headline":"New study assesses the efficacy of suvorexant in reducing delirium in older adults - EurekAlert!","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTFBtTTc3U0l6OEdoSmxYcFhxTmZMeFU2SUZWbEhEekZ3MXNNUUdKUVRPQVZJT01nVmIwYndYcmJpMC1iN2Nqdmx3QVRENUVOLTRTRVBfWjAwemFQRkVmNm9zckl0YS1fSG9sdkE?oc=5","date":"2024-04-25","type":"pipeline","source":"Wiley Online Library","summary":"Respirology Case Reports | APSR Respiratory Medicine Journal - Wiley Online Library","headline":"Respirology Case Reports | APSR Respiratory Medicine Journal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOYnlLVWVRanhNRjZrVFpZbmZkbU9tNi1ubmFGRy1ZY0xRdFVVdDFPRGRrQnAwazBsOG1paGhhc3VvN1p0aVJhYWVaSUlybWNwN25ZaEFxRHhmNU9xaC1oeXIzS2hURzQ3TllMMFpxX3lpWjN0dThaSWNZUFFaQ2ZhSDM2WHpfQndXUnZqSWU5d0NXR2lfQUE?oc=5","date":"2024-02-12","type":"pipeline","source":"Fortune Business Insights","summary":"Japan Tardive Dyskinesia Therapeutics Market Trends - Fortune Business Insights","headline":"Japan Tardive Dyskinesia Therapeutics Market Trends","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE9DQUFxQTNjaFBja2VpTnB0QW95Z0FfTXFyeDF3Z1lmSmllYTliVWU4SG1rWXlHS0tZNVFuZkd4Yi1Nb2oyamczYVh5c2w2Y1I0a3BMNWZyU2ZkQzhnM1lFX2JaTHVyaHRNQ3c?oc=5","date":"2023-09-15","type":"pipeline","source":"Wiley Online Library","summary":"Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK -rearranged non-small cell lung cancer - Wiley Online Library","headline":"Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK -rearranged non-small cell lung cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBJNlhyazd6ZEF6aUZMcUJaT245QlJ1Z0VaWHhMWUNjTjdobF9KQjNWRzJFMGE4cWdFR00tNDYtSjFheTNreS1hRlZOZ3BSTVdwTHppUHQwZWUwdTVPcmRr?oc=5","date":"2023-03-29","type":"pipeline","source":"Nature","summary":"Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin - Nature","headline":"Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE9ERVJBZFBGaEZwTERhMTFLa0IzcEhHbjFwNUVORHBLeGJaVWR3a21WekhqRV9VblJtU0wzVlQtX2dMb041akM4a0RqZEFreHRjZTBGYkMzQjZDQndPalNoeW5Kbml3Sy1LMVE?oc=5","date":"2022-06-29","type":"pipeline","source":"Wiley Online Library","summary":"Does castration status affect docetaxel‐related adverse events? :Identification of risk factors for docetaxel‐related adverse events in metastatic prostate cancer - Yanagisawa - 2022 - The Prostate - ","headline":"Does castration status affect docetaxel‐related adverse events? :Identification of risk factors for docetaxel‐related ad","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTE5kUVZmWmw5THhhcVVZbnktazByQ2NpUmZoY0Q1ZEhyT3NsRHJ5RjBrT0RELVJzRklTOTZpWUptNHVFUlhuY08yMU9BNW54bnpHc0ZQbGsyU0E?oc=5","date":"2019-12-19","type":"pipeline","source":"Nature","summary":"Dementia and Drug Discovery / Janssen Pharmaceuticals K.K. - Nature","headline":"Dementia and Drug Discovery / Janssen Pharmaceuticals K.K.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBva2M2VXV1QVhlSVQ2QXhabVo3QUk4SDZ3a0tWSUpieDJXOVlVcTVuX3RoOWpHcEFnRWFJeFVCM2JQR2xmMDFTWFZieU1zaTVEeUpGWmFsdWtFY2hacGp3?oc=5","date":"2019-03-21","type":"pipeline","source":"Nature","summary":"Drug pipelines need more academic input - Nature","headline":"Drug pipelines need more academic input","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxOdGg4d0JrcWgwNV94RWZEUVlYYnAxYlFSOU55RnBYQW1pY3FCSEJYOGlhWnhlUEpaNXA4MU5mOWl3WUZjdXk0UUhvcjBqX2JvSmQ5eUkwcjdjTmZ3NjlYUFpMQjYteXdHM1hvMWpGNFZON0l1aTBlcWdtM2hpdEFWVFhzR2NtOWExZldybmpzQlBrb2phbjlpaTBtbTEyOWNCeVY1allOTmJyam95U3dPa2lHZHFMV3FnWnFqdU44cXhDbFRB?oc=5","date":"2013-10-11","type":"pipeline","source":"AstraZeneca","summary":"AstraZeneca enters co-promotion agreement with Janssen in Japan for innovative prostate cancer treatment - AstraZeneca","headline":"AstraZeneca enters co-promotion agreement with Janssen in Japan for innovative prostate cancer treatment","sentiment":"neutral"}],"patents":[],"drugCount":11,"phaseCounts":{"phase_3":7,"phase_2":2,"phase_1":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}